Role of aspirin in modulating myocardial ischemic reperfusion injury.
The role of low-dose aspirin (3 mg/kg, i.v.) in attenuating ischemic reperfusion injury was studied in a canine model. Regional ischemia for 40 min was produced by temporary occlusion of the left anterior descending coronary artery and thereafter reperfusion instituted for 3 h. Mean arterial pressure (MAP), heart rate (HR), left ventricular end diastolic pressure (LVEDP), positive (+) LV dP/dtmax and negative (-) LV dP/dtmax were monitored along with myocardial adenosine triphosphate (ATP), creatine phosphate (CP), glycogen and lactate. Following reperfusion, there was a significant fall in (i) MAP, (ii) (+) LV dP/dtmax and (iii) (-) LV dP/dtmax. LVEDP was corrected after about 2 h of reperfusion. Replenishment of only myocardial CP occurred, without any change in ATP and glycogen, although lactate accumulation was corrected. Aspirin administered 15 min before reperfusion (post-treatment) caused normalisation of LVEDP within 15 min and prevented any deterioration in (-) LV dP/dtmax, although it had no effect on MAP and (+) LV dP/dtmax. After 3 h of reperfusion (post-treatment), myocardial ATP, CP, glycogen and lactate contents became normal. The number of premature ventricular complexes was significantly reduced after aspirin treatment. The present study indicates that low-dose aspirin post-treatment can ameliorate at least some of the deleterious consequences of reperfusion injury of the myocardium.
Seth
S D
SD
Department of Pharmacology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi.
Maulik
M
M
Manchanda
S C
SC
Maulik
S K
SK
D000255:Adenosine Triphosphate / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000378:metabolism; D004195:Disease Models, Animal; D004285:Dogs; D006003:Glycogen / Q000378:metabolism; D006339:Heart Rate / Q000187:drug effects; D007275:Injections, Intravenous; D007773:Lactates / Q000378:metabolism; D019344:Lactic Acid; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000401:mortality; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy*
D007773:Lactates; D019344:Lactic Acid; D000255:Adenosine Triphosphate; D006003:Glycogen; D003404:Creatinine; D001241:Aspirin